Axiom Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 04-07-2024
- Paid Up Capital ₹ 0.10 M
as on 04-07-2024
- Company Age 15 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.16 M
as on 04-07-2024
- Revenue 86.46%
(FY 2023)
- Profit 52.98%
(FY 2023)
- Ebitda 327.70%
(FY 2023)
- Net Worth 46.69%
(FY 2023)
- Total Assets 44.15%
(FY 2023)
About Axiom Pharma
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.16 M.
Ajay Singh and Gautam Kartik serve as directors at the Company.
- CIN/LLPIN
U24232RJ2009PTC029780
- Company No.
029780
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Sep 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Axiom Pharma Private Limited offer?
Axiom Pharma Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Common Disease Medicines, Thyroxine Sodium Tablets, Immunization & Vaccination Drugs, Vaccines, Pharmaceutical Medicine, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Pharmaceutical Tablets.
Who are the key members and board of directors at Axiom Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Singh  | Director | 16-Jan-2015 | Current |
| Gautam Kartik | Director | 16-Jan-2015 | Current |
Financial Performance of Axiom Pharma.
Axiom Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 86.46% increase. The company also saw a substantial improvement in profitability, with a 52.98% increase in profit. The company's net worth Soared by an impressive increase of 46.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Axiom Pharma?
In 2023, Axiom Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 05 May 2023 | ₹3.50 M | Open |
Hdfc Bank Limited Creation Date: 05 Aug 2022 | ₹1.05 M | Open |
Hdfc Bank Limited Creation Date: 31 May 2021 | ₹0.61 M | Open |
How Many Employees Work at Axiom Pharma?
Unlock and access historical data on people associated with Axiom Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Axiom Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Axiom Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
